fda glp-1 warning news november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia FDA Approves Orforglipron, First GLP-1

A dose injected into lipohypertrophic tissue may absorb unpredictably, leading to inconsistent blood levels and reduced effectiveness

P 0.10), as shown in Table 1

Who Should Choose Tirzepatide: Ideal Candidates: Need maximum weight loss (50+ pounds) Want most effective medication available Can afford $349-$1,069/month depending on option Have BMI 30 (or 27 with comorbidities) Plateaued on semaglutide or other medications No contraindications to GLP-1/GIP agonists Particularly Good For: Significant obesity (BMI 35) Previous weight loss medication failures Those who want best possible results Patients who tolerate GLP-1s well Cost Comparison: Value Analysis: Cost per % Body Weight Lost: Brand-Name Tirzepatide: 22.5% loss at $12,828/year Cost per %: $570 Compounded Tirzepatide (TrimRx): 22.5% loss at $4,188/year Cost per %: $186 Compounded Semaglutide (TrimRx): 14.9% loss at $2,388/year Cost per %: $160 Both compounded options offer excellent value, with semaglutide being slightly more cost-efficient per percentage lost, while tirzepatide produces greater absolute weight loss

Exenatide efficacy and safety: a systematic review

But how exactly